Richmond Pharmacology presents further QT insulin data next month in San Diego!

Posted:
30
August 2012

30th August 2012

Richmond Pharmacology presents further QT insulin data next month in San Diego!

We welcome you to attend the 2012 Annual Meeting of the American College of Clinical Pharmacology (ACCP), taking place 23rd-25th September, at the Sheraton San Diego Hotel & Marina.This topic of this year's meeting is  Translating Clinical Pharmacology Research into Optimized Patient Care  and will encompass a series of Pre-meeting Workshops and Symposia on related content such as the role of clinical pharmacology in speeding the development of new anti-infective drugs to combat drug resistance, pharmacometrics in hospital-based pharmacotherapy, innovations in drug therapies, and much more.Join Richmond Pharmacology on Day 1, Sun 23rd Sep between 6 and 8pm, where we will present further data on studies using techniques such as the euglycaemic insulin clamp to probe the effect of insulin on the QT interval in healthy Caucasian and Japanese volunteers:

  • Late changes after a euglycaemic insulin clamp can lead to significant increases in QTcF in healthy subjects
  • The impact of insulin levels on QTc interval in Thorough QT studies conducted in healthy subjects

View full program

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more